KRChoksey's research report on Cipla
Cipla reported Revenue growth of 9.0% YoY (-0.7% QoQ) to INR 43,462 mn in 1QFY21 on the back of strong growth in the domestic market, Europe, Emerging Markets & SAGA region. EBITDA for the quarter rose 15.9% YoY (+65.5% QoQ) to INR 10,487 mn. EBITDA margin expanded 145 bps YoY to 24.1% in 1QFY21 (from 22.7% in last year). On sequential basis, EBITDA margin expanded 965 bps QoQ from 14.5% in 4QFY20. Net Profit rose 20.9% YoY (up 135% QoQ). Net Profit Margin for the quarter expanded 131 bps YoY to 13.3% (up 768 bps QoQ). R&D investment for the quarter stood at INR 2.0 bn at 4.6% of sales. Company has 262 ANDAs as of 30th June 2020, with 66 ANDAs pending for USFDA approval.
Outlook
We are optimistic of company’s growth prospects and continue to apply P/E multiple of 24.5x on FY22E EPS of INR 36.5/share & raise our target price to INR 894 per share (previous TP: INR 700/share) ; an upside potential of 15%. Accordingly, we reiterate a “BUY” rating on the shares of Cipla.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.